NCT00447356撤回3 期
Phase III Randomized Study of Four Weeks High Dose IFN-2b in StageT3-T4 or N1 (Microscopic) Melanoma
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 试验地点
- 2
研究概览
简要总结
This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.
详细描述
Interferon alfa may interfere with growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed primary melanoma of cutaneous origin
- •Stage II (T3 N0 M0 1.5-4.0mm Breslow depth
- •Clinically negative regional lymph node pathologic status unkown OR
- •Histologically negative regional lymph nodes
- •Stage III (T4 N0 M0)
- •Greater than 4.0mm Breslow depth OR
- •Stage III (T1-4 N1)
- •One lymph node positive microscopically
- •Patients must meet at least 1 of the following criteria
- •T2b N0 primary melanoma 1.01-2.0mm with ulceration, node negative
- •T3a-b N0 primary melanoma 2.01-4.0mm with and without ulceration, node negative
- •T4a-b N0 primary melanoma > 4.0mm with and without ulceration, node negative
- •T1aN1a-2a (microscopic)-primary melanoma of any thickness with microscopically positive lymph node (any number)
- •Note EORTC patients who are node negative T2 or T3 are ineligible
- •Patients with positive sentinel node should undergo complete lymphadenectomy of the nodal basin prior to study
- •Must complete all primary therapy (wide excision with or without lymphadenectomy) and be randomized in the study within 84 days of wide excision
- •No clinical, radiological/laboratory, or pathological evidence of incompletely resected melanoma or any distant metastatic disease
- •No clinically palpable lymphadenopathy
- •18 and over
- •Performance Status:
- •Life expectancy:
- •Not specified Hematopoietic
- •WBC at least 3,000/mm^3
- •Platelet count at least 125,000/mm^3
- •Hematocrit at least 30%
- •Bilirubin no greater than 2 times the upper limit of normal (ULN)
- •AST, LDH, and Alkaline phosphate no greater than 2 times ULN
- •If lactate dehydrogenase or alkaline phosphate is above normal, a contrast enhanced CT scan or MRI of the liver is required to document the absence of tumor
- •BUN no greater than 33mg/dl OR
- •Creatinine no greater than 1.8mg/dl
- •Cardiovascular:
- •No history of active ischemic heart disease
- •No cerebrovascular disease
- •No congestive heart failure(New York Heart Association class III or IV heart disease)
排除标准
- •Biologic Therapy:
- •No prior immunotherapy including tumor vaccines, interferon, interleukins,levamisole, or other biologic response modifers for melanoma Chemotherapy
- •No prior or concurrent chemotherapy Endocrine Therapy
- •No concurrent systemic corticosteriods including oral steriods (i.e., prednisone, dexamethasone), topical steroid creams or ointments, or any steriod-containing inhalers.
- •Radiotherapy:
- •No Prior or concurrent radiotherapy
- •See Disease characteristics
- •No other concurrent immunosuppressive medications
- •No other history of invasive melanoma
- •No autoimmune disorders or conditions of immunosuppression
- •No other concurrent or prior malignancies within past 5 years
- •Cancer in situ
- •Lobular carcinoma in situ of breast
- •Carcinoma in situ of the cervix
- •Atypical melanocytic hyperplasia or Clark 1 melanoma in situ
- •Basal or squamous cell skin cancer
- •No evidence of organic brain syndrome or significant impairment of basal cognitive function or any psychiatric disorder that would preclude study participation
- •No other significant medical or surgical condition, or any medication or treatment regimens, that would interfere with study participation.
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for 6 months after study
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis CHepatitis CNCT00004804National Center for Research Resources (NCRR)57
进行中（未招募）
3 期
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III MelanomaMelanoma (Skin)NCT00003641ECOG-ACRIN Cancer Research Group1,150
Unknown
3 期
A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade GliomasAnaplastic OligoastrocytomaAnaplastic AstrocytomaGlioblastomaNCT01765088Sun Yat-sen University300
进行中（未招募）
3 期
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryMelanoma of Unknown PrimaryRecurrent MelanomaStage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7NCT01274338National Cancer Institute (NCI)1,673
已完成
4 期
A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 InfectionHepatitis C, ChronicNCT00192647Hoffmann-La Roche896